tiprankstipranks
Trending News
More News >
Zura Bio (ZURA)
NASDAQ:ZURA

Zura Bio (ZURA) AI Stock Analysis

Compare
407 Followers

Top Page

ZU

Zura Bio

(NASDAQ:ZURA)

38Underperform
Zura Bio's overall financial health is concerning due to lack of revenue and increasing losses, despite a strong cash position. The technical indicators suggest a bearish trend with no immediate reversal signals. The company's valuation metrics highlight the risks associated with unprofitable biotech firms. Improvement in revenue generation and cost management is crucial for future stock performance.
Positive Factors
Financial Stability
Zura ended 2024 with roughly $176.5M in cash and cash equivalents, which management expects to provide an operational runway through 2027.
Study Design
The thoughtfully crafted nature of the study design aims to succeed on the primary endpoint and provide derisking data for lung outcomes, potentially facilitating a move into a Phase 3 study.
Trial Developments
ZURA plans to initiate a Ph 2 trial of lead asset tibulizumab in hidradenitis suppurativa (HS), and they now have an active IND for this indication.
Negative Factors
Clinical Data
The lackluster clinical data generated to date, with no clear dose-dependent response in B cell count reductions and an increase in IL-17A target engagement observed at the highest dose in the post-dosing follow-up period.
Regulatory Risks
The broader development-stage biotech landscape has seen heightened regulatory risks stemming from the recent FDA shakeup.
Stock Price Target
The net effect is a reduction in the 12-month price target to $3 from the prior $5 per share.

Zura Bio (ZURA) vs. S&P 500 (SPY)

Zura Bio Business Overview & Revenue Model

Company DescriptionZura Bio (ZURA) is a biotechnology company focused on the development and commercialization of innovative therapies for immune-mediated and fibrotic diseases. The company operates within the healthcare sector, specifically targeting the biopharmaceutical industry. Zura Bio's core products are centered around its proprietary drug candidates that aim to address unmet medical needs by modulating complex biological pathways involved in immune system regulation and tissue fibrosis.
How the Company Makes MoneyZura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary
Zura Bio faces financial challenges with no revenue generation and increasing losses. However, its strong cash position and absence of debt offer short-term stability. The company must improve operational efficiencies and explore revenue-generating strategies to ensure long-term viability.
Income Statement
20
Very Negative
Zura Bio has consistently reported zero revenue over the past three years, with increasing net losses. This reflects a challenging financial position in terms of generating income. The negative EBIT and EBITDA margins further highlight inefficiencies in cost management or lack of operational revenues.
Balance Sheet
40
Negative
The balance sheet shows a strong cash position with no debt, which provides a buffer against operational losses. The company's equity has significantly improved over the years, moving from negative to positive, indicating some financial recovery. However, the lack of revenue generation is a concern despite the strong cash reserves.
Cash Flow
35
Negative
Operating cash flow remains negative, reflecting ongoing operational challenges. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. While financing cash flow is positive, suggesting successful fundraising efforts, reliance on external financing could be risky without revenue improvement.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021
Income StatementTotal Revenue
0.000.000.000.00
Gross Profit
0.000.000.000.00
EBIT
-55.19M-62.64M-2.68M-1.09M
EBITDA
-55.19M-60.56M-27.33M8.42M
Net Income Common Stockholders
-45.39M-60.36M3.55M8.42M
Balance SheetCash, Cash Equivalents and Short-Term Investments
176.50M99.81M13.79K4.72M
Total Assets
179.53M100.84M141.51M4.72M
Total Debt
0.000.00355.60K0.00
Net Debt
-176.50M-99.81M341.81K-4.72M
Total Liabilities
19.51M21.29M14.82M39.00K
Stockholders Equity
146.81M59.33M-32.06M4.68M
Cash FlowFree Cash Flow
-28.15M-23.05M-13.07M-1.10M
Operating Cash Flow
-28.08M-15.05M-1.07M-1.10M
Investing Cash Flow
-5.08M-8.00M-12.00M-139.38M
Financing Cash Flow
109.84M121.29M355.60K141.21M

Zura Bio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.44
Price Trends
50DMA
1.29
Positive
100DMA
1.76
Negative
200DMA
2.83
Negative
Market Momentum
MACD
<0.01
Negative
RSI
58.47
Neutral
STOCH
85.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Positive. The current price of 1.44 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.29, and below the 200-day MA of 2.83, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.47 is Neutral, neither overbought nor oversold. The STOCH value of 85.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZURA.

Zura Bio Risk Analysis

Zura Bio disclosed 84 risk factors in its most recent earnings report. Zura Bio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Zura Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.31B3.33-39.82%2.92%17.95%1.84%
49
Neutral
$86.93M-58.80%-100.00%-24.28%
44
Neutral
$94.63M-31.39%15.09%
38
Underperform
$98.46M-44.03%86.65%
35
Underperform
$92.76M-70.13%1.27%
34
Underperform
$77.72M-47.99%-71.01%-14.04%
30
Underperform
$80.88M-9999.00%27.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZURA
Zura Bio
1.44
-2.97
-67.35%
ATOS
Atossa Therapeutics
0.73
-0.80
-52.29%
ANIX
Anixa Biosciences
2.76
-0.47
-14.55%
ELTX
Elicio Therapeutics
5.13
-3.86
-42.94%
CRBU
Caribou Biosciences
0.77
-2.94
-79.25%
HLVX
HilleVax, Inc
1.85
-10.94
-85.54%

Zura Bio Corporate Events

Business Operations and Strategy
Zura Bio to Participate in Global Healthcare Conference
Neutral
Feb 24, 2025

On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.